Floreane's Sofradim builds US structure
This article was originally published in Clinica
Sofradim, the US subsidiary set up by France's Floreane Medical Implants, is targeting the establishment of a US sales force of up to 40 representatives in the near future, says the Trevoux-based parent company. Sofradim, which recently expanded its management staff to five under president William Barrett, is currently planning distribution of its newly approved urological implant, Uretex. Its business so far has been from early sales of four FDA-approved parietal implants. The Boston-based subsidiary has made sales of E90,000 ($80,000) in its first three months of operation, and has targeted full-year 2002 sales of E1 million.